Patents by Inventor Moise Azria
Moise Azria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9622975Abstract: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.Type: GrantFiled: May 21, 2015Date of Patent: April 18, 2017Assignee: Novartis AGInventors: Moise Azria, Simon David Bateman, Anasuya Ashok Ghosh, Shoufeng Li, Alan Edward Royce
-
Patent number: 9272040Abstract: Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.Type: GrantFiled: December 15, 2011Date of Patent: March 1, 2016Assignee: Novartis AGInventors: Moise Azria, Simon David Bateman
-
Publication number: 20150250729Abstract: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.Type: ApplicationFiled: May 21, 2015Publication date: September 10, 2015Inventors: Moise Azria, Simon David Bateman, Anasuya Ashok Ghosh, Shoufeng Li, Alan Edward Royce
-
Publication number: 20140271735Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: ApplicationFiled: June 2, 2014Publication date: September 18, 2014Applicant: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 8835389Abstract: The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutically acceptable oral delivery form, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin.Type: GrantFiled: November 3, 2006Date of Patent: September 16, 2014Assignees: Novartis AG, Nordic Bioscience A/SInventors: Moise Azria, Claus Christiansen
-
Patent number: 8765675Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: GrantFiled: June 21, 2010Date of Patent: July 1, 2014Assignee: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 8748383Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.Type: GrantFiled: April 15, 2013Date of Patent: June 10, 2014Assignees: Novartis AG, Emisphere Technologies, Inc.Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
-
Patent number: 8664211Abstract: A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.Type: GrantFiled: December 15, 2011Date of Patent: March 4, 2014Assignee: Novartis AGInventors: Simon David Bateman, Moise Azria
-
Patent number: 8658695Abstract: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. Preferred delivery agents include, but are not limited to, N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). The invention also provides methods of preparing the disodium salt, ethanol solvate, and hydrate and compositions containing the disodium salt, ethanol solvate, and/or hydrate.Type: GrantFiled: May 25, 2012Date of Patent: February 25, 2014Assignees: Emisphere Technologies, Inc., Novartis AGInventors: William Elliott Bay, Rajesh K. Agarwal, Kiran Chaudhary, Shingai Majuru, Michael M. Goldberg, JoAnne P. Corvino, Moise Azria, Joseph Ault, Simon D. Bateman, Subash Patel, Joseph Sikora, Rebecca F. Yang, Joseph Zielinski
-
Publication number: 20130230593Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
-
Patent number: 8435946Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.Type: GrantFiled: June 4, 2008Date of Patent: May 7, 2013Assignees: Novartis AG, Emisphere Technologies, Inc.Inventors: Shoufeng Li, Anasuya A Ghosh, Simon D Bateman, Moise Azria, Alan E Royce
-
Patent number: 8323688Abstract: The present invention relates to dosage forms of human growth hormone, the use of an absorption enhancer to allow absorption of human growth hormone into the systemic circulation in a biologically active form, in particular after oral administration, as well as the use of oral dosage forms comprising human growth hormone and an absorption enhancer for the treatment of human growth hormone deficiencies and disorders associated therewith.Type: GrantFiled: August 28, 2007Date of Patent: December 4, 2012Assignee: Novartis AGInventors: Moise Azria, Yatindra Joshi, Rosario Lobrutto, Linda Mindeholm, Ashish B Patel
-
Publication number: 20120264834Abstract: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. Preferred delivery agents include, but are not limited to, N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). The invention also provides methods of preparing the disodium salt, ethanol solvate, and hydrate and compositions containing the disodium salt, ethanol solvate, and/or hydrate.Type: ApplicationFiled: May 25, 2012Publication date: October 18, 2012Applicants: NOVARTIS AG, Emisphere Technologies, Inc.Inventors: William E. BAY, Rajesh K. AGARWAL, Kiran CHAUDHARY, Shingai MAJURU, Michael M. GOLDBERG, JoAnne P. CORVINO, Moise AZRIA, Joseph M. AULT, Simon D. BATEMAN, Subash PATEL, Joseph SIKORA, Rebecca F. YANG, Joseph L. ZIELINSKI
-
Publication number: 20120219603Abstract: The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutically acceptable oral delivery form, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin.Type: ApplicationFiled: March 1, 2012Publication date: August 30, 2012Inventors: Moise AZRIA, Claus Christiansen
-
Patent number: 8207227Abstract: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. The delivery agents have the formula wherein R1, R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, or C1-C4 alkoxy; and R5 is a substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted C2-C16 alkenylene, substituted or unsubstituted C1-C12 alkyl(arylene), or substituted or unsubstituted aryl(C1-C12 alkylene). The hydrates and solvates of present invention also have surprisingly greater efficacy for delivering active agents, such as heparin and calcitonin, than their corresponding monosodium salts and free acids. The present invention provides an alcohol solvate, such as ethanol solvate, of a disodium salt of a delivery agent of the formula above.Type: GrantFiled: March 22, 2011Date of Patent: June 26, 2012Assignees: Emisphere Technologies, Inc., Novartis AGInventors: William E. Bay, Rajesh K. Agarwal, Kiran Chaudhary, Michael M. Goldberg, Joanne P. Corvino, Shingai Majuru, Moise Azria, Joseph Ault, Simon D. Bateman, Subash Patel, Joseph Sikora, Rebecca F. Yang, Joseph Zielinski
-
Publication number: 20120088833Abstract: A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Inventors: Simon David BATEMAN, Moise AZRIA
-
Publication number: 20120088725Abstract: Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Inventors: Moise Azria, Simon David Bateman
-
Patent number: 8153587Abstract: A method for orally administering a parathyroid hormone, PTH, comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of calcitonin. The method according to the invention allows for the oral administration of PTH without the hypercalcemia, hypercalcuria and nephrolithiasis side effects.Type: GrantFiled: January 28, 2008Date of Patent: April 10, 2012Assignee: Novartis AGInventors: Joseph M Ault, Moise Azria, Simon D Bateman, James F McLeod
-
Publication number: 20110251125Abstract: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. The delivery agents have the formula wherein R1, R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, or C1-C4 alkoxy; and R5 is a substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted C2-C16 alkenylene, substituted or unsubstituted C1-C12 alkyl(arylene), or substituted or unsubstituted aryl(C1-C12 alkylene). The hydrates and solvates of present invention also have surprisingly greater efficacy for delivering active agents, such as heparin and calcitonin, than their corresponding monosodium salts and free acids. The present invention provides an alcohol solvate, such as ethanol solvate, of a disodium salt of a delivery agent of the formula above.Type: ApplicationFiled: March 22, 2011Publication date: October 13, 2011Applicants: Novartis AG, Emisphere Technologies, Inc.Inventors: William E. Bay, Rajesh K. Agarwal, Kiran Chaudhary, Shingai Majuru, Michael M. Goldberg, Joanne P. Corvino, Moise Azria, Joseph M. Ault, Simon D. Bateman, Subash Patel, Joseph Sikora, Rebecca F. Yang, Joseph L. Zielinski
-
Publication number: 20110218148Abstract: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly(amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly(amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.Type: ApplicationFiled: April 4, 2011Publication date: September 8, 2011Inventors: Moise Azria, Simon David Bateman, Anasuya Ashok Ghosh, Shoufeng Li, Alan Edward Royce